Anaesthesia’s Hobson’s choice: The brave new world of glucagon-like peptide-1 receptor agonists (GLP-1RAs)

Kranjac AW Kranjac D. Explaining adult obesity, severe obesity, and BMI: Five decades of change. Heliyon 2023; 9: e16210. doi:10.1016/j.heliyon.2023.e16210

World Health Organization. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed 6 June 2025).

Australian Institute of Health and Welfare (2024) Overweight and obesity, AIHW, Australian Government. https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity/contents/overweight-and-obesity (accessed 6 June 2025).

Schetz M De Jong A Deane AM , et al. Obesity in the critically ill: A narrative review. Intensive Care Med 2019; 45: 757–769. doi:10.1007/s00134-019-05594-1

Van Gaal LF Mertens IL De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875–880. doi:10.1038/nature05487

Aurigemma GP de Simone G Fitzgibbons TP. Cardiac remodeling in obesity. Circ Cardiovasc Imaging 2013; 6: 142–152. doi:10.1161/CIRCIMAGING.111.964627

Pati S Irfan W Jameel A , et al. Obesity and cancer: A Current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel) 2023; 15: 485. doi:10.3390/cancers15020485

Kassahun WT Mehdorn M Babel J. The impact of obesity on surgical outcomes in patients undergoing emergency laparotomy for high-risk abdominal emergencies. BMC Surg 2022; 22: 15. doi:10.1186/s12893-022-01466-6

Cullinane C Fullard A Croghan SM , et al. Effect of obesity on perioperative outcomes following gastrointestinal surgery: meta-analysis. BJS Open 2023; 7: zrad026. doi:10.1093/bjsopen/zrad026

Peri K Eisenberg M. Review on the update in obesity management: Epidemiology. BMJ Public Health 2024; 2: e000247. doi:10.1136/bmjph-2023-000247

Hruby A Hu FB. The epidemiology of obesity: A big picture. Pharmacoeconomics 2015; 33: 673–689. doi:10.1007/s40273-014-0243-x

Machado PP Steele EM Levy RB , et al. Ultra-processed food consumption and obesity in the Australian adult population. Nutr Diabetes 2020; 10: 39. doi:10.1038/s41387-020-00141-0

Lane MM Gamage E Du S , et al. Ultra-processed food exposure and adverse health outcomes: Umbrella review of epidemiological meta-analyses BMJ 2024; 384: e077310. doi:10.1136/bmj-2023-077310

Schauer PR Kashyap SR Wolski K , et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567–1576. doi:10.1056/NEJMoa1200225

Ells LJ Rees K Brown T , et al. Interventions for treating children and adolescents with overweight and obesity: An overview of Cochrane reviews. Int J Obes 2018; 42: 1823–1833. doi:10.1038/s41366-018-0230-y

Shariq Usman M Davies M Hall ME , et al. The cardiovascular effects of novel weight loss therapies. Eur Heart J 2023; 44: 5036–5048. doi:10.1093/eurheartj/ehad664

Alfaris N Waldrop S Johnson V , et al. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: A narrative review. eClinicalMedicine 2024; 75: 102782. doi:10.1016/j.eclinm.2024.102782

Philippe J Powers AC. Observations on the discovery of glucagon-like peptide-1 action. JAMA 2025; 333(22): 1951–1952. doi:10.1001/jama.2025.5142.

Wilding JPH Batterham RL Calanna S , et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989–1002. doi:10.1056/NEJMoa2032183

Kosiborod MN Abildstrøm SZ Borlaug BA , et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023; 389: 1069–1084. doi:10.1056/NEJMoa2306963

Kosiborod MN Petrie MC Borlaug BA , et al; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024; 390: 1394–1407. doi:10.1056/NEJMoa2313917

Packer M Zile MR Kramer CM , et al; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025; 392: 427–437. doi:10.1056/NEJMoa2410027

Loomba R Hartman ML Lawitz EJ , et al; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024; 391: 299–310. doi:10.1056/NEJMoa2401943

Tang H Donahoo WT DeKosky ST , et al. GLP-1RA and SGLT2i medications for type 2 diabetes and Alzheimer disease and related dementias. JAMA Neurol. Epub ahead of print 7 April 2025. doi:10.1001/jamaneurol.2025.0353

Seminer A Mulihano A O’Brien C , et al. Cardioprotective glucose-lowering agents and dementia risk. A systematic review and meta-analysis. JAMA Neurol 2025; 82(5): 450–460. doi:10.1001/jamaneurol.2025.0360

Wang L Xu R Kaelber DC , et al. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open 2024; 7: e2421305. doi:10.1001/jamanetworkopen.2024.21305

Ashruf OS Hundal J Mushtaq A , et al. Hematologic cancers among patients with type 2 diabetes prescribed GLP-1 receptor agonists. JAMA Netw Open 2025; 8: e250802. doi:10.1001/jamanetworkopen.2025.0802

Klausen MK Thomsen M Wortwein G , et al. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol 2022; 179: 625–641. doi:10.1111/bph.15677

Lähteenvuo M Tiihonen J Solismaa A , et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry 2025; 82: 94–98. doi:10.1001/jamapsychiatry.2024.3599

Ostrominski JW Ortega-Montiel J Tesfaye H , et al. Trends in utilization of glucose- and weight-lowering medications after tirzepatide approval in the United States: A population-based cohort study. Ann Intern Med. Epub ahead of print 15 April 2025. doi:10.7326/ANNALS-24-02870

Hulst AH Plummer MP Hollmann MW , et al. Systematic review of incretin therapy during peri-operative and intensive care. Crit Care 2018; 22: 299. doi:10.1186/s13054-018-2197-4

Järvholm K Janson A Henfridsson P , et al. Metabolic and bariatric surgery for adolescents with severe obesity: Benefits, risks, and specific considerations. Scand J Surg 2025; 114: 95–106. doi:10.1177/14574969241297517.

Drucker DJ. The GLP-1 journey: From discovery science to therapeutic impact. J Clin Invest 2024; 134: e175634. doi:10.1172/JCI175634

Beam WB Hunter Guevara LR. Are serious anesthesia risks of semaglutide and other GLP-1 agonists under-recognized? Case reports of retained solid gastric contents in patients undergoing anesthesia. APSF Newsletter 2023; 38: 67,69–71.

Silveira SQ da Silva LM de Campos Vieira Abib A , et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth 2023; 87: 111091. doi:10.1016/j.jclinane.2023.111091

Sherwin M Hamburger J Katz D , et al. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: A prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth 2023; 70: 1300–1306. doi:10.1007/s12630-023-02549-5

Pfeifer KJ Selzer A Mendez CE , et al. Preoperative management of endocrine, hormonal, and urologic medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc 2021; 96: 1655–1669. doi:10.1016/j.mayocp.2020.10.002

Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. CPOC, 2021, https://cpoc.org.uk/sites/cpoc/files/documents/2021-03/CPOC-Diabetes-Guideline2021_0.pdf (accessed 15 August 2023).

Hulst AH Polderman JAW Siegelaar SE , et al. Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. Br J Anaesth 2021; 126: 567–571. doi:10.1016/j.bja.2020.10.023

American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagonlike peptide-1 (GLP-1) receptor agonists, https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-ofanesthesiologists-consensus-based-guidance-on-preoperative (accessed 6 June 2025).

Gariani K Putzu A. Glucagon-like peptide-1 receptor agonists in the perioperative period: Implications for the anaesthesiologist. Eur J Anaesthesiol 2024; 41: 245–246. doi:10.1097/EJA.0000000000001914

American Gastroenterological Association. No data to support stopping GLP-1 agonists prior to elective endoscopy. Multi-society statement, 11 August 2023, https://gastro.org/news/gi-multi-society-statement-regarding-glp-1-agonists-and-endoscopy/ (accessed November 2023).

Kindel TL Wang AY Wadhwa A , et al; Representing the American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, American Society of Anesthesiologists, International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc 2025; 39: 180–183. doi:10.1007/s00464-024-11263-2

Engelhardt T Webster NR. Pulmonary aspiration of gastric contents in anaesthesia. Br J Anaesth 1999; 83: 453e60. doi:10.1093/bja/83.3.453

Hocking SL, Scott DA, Remedios ML, et al. Clinical practice recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures. https://www.anzca.edu.au/getContentAsset/0f35028e-e371-4220-a49a-ddee877051c8/80feb437-d24d-46b8-a858-4a2a28b9b970/Periprocedural-GLP-1-use-consensus-clinical-guide_P2.pdf (accessed 6 June 2025).

Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric content and aspiration in patients undergoing gastrointestinal endoscopy: A systematic review and a metaanalysis. Gastrointest Endosc 2024. doi:10.1016/j.gie.2024.12.019

Chen Y Zink T Chen Y , et al. Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists. JAMA Netw Open 2025; 8: e250081. doi:10.1001/jamanetworkopen.2025.0081

El-Boghdadly K Wojcikiewicz T and Perlas A. Perioperative point-of-care gastric ultrasound. BJA Educ 2019; 19: 219–226. doi:10.1016/j.bjae.2019.03.003

Hashim MM Ismail MA Esmat AM , et al. Difficult tracheal intubation in bariatric surgery patients, a myth or reality? Br J Anaesth 2016; 116: 557–558. doi:10.1093/bja/aew039